The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Duchenne Muscular Dystrophy: From Diagnosis to Therapy
Open accessAbstract
Duchenne muscular dystrophy (DMD) is an X-linked inherited neuromuscular disorder due to mutations in the dystrophin gene. It is characterized by progressive muscle weakness and wasting due to the absence of dystrophin protein that causes degeneration of skeletal and cardiac muscle. The molecular diagnostic of DMD involves a deletions/duplications analysis performed by quantitative technique such as microarray-based comparative genomic hybridization (array-CGH), Multiple Ligation Probe Assay MLPA. Since traditional methods for detection of point mutations and other sequence variants require high cost and are time consuming, especially for a large gene like dystrophin, the use of next-generation sequencing (NGS) has become a useful tool available for clinical diagnosis. The dystrophin gene is large and finely regulated in terms of tissue expression, and RNA processing and editing includes a variety of fine tuned processes. At present, there are no effective treatments and the steroids are the only fully approved drugs used in DMD therapy able to slow disease progression. In the last years, an increasing variety of strategies have been studied as a possible therapeutic approach aimed to restore dystrophin production and to preserve muscle mass, ameliorating the DMD phenotype. RNA is the most studied target for the development of clinical strategies and Antisense Oligonucleotides (AONs) are the most used molecules for RNA modulation. The identification of delivery system to enhance the efficacy and to reduce the toxicity of AON is the main purpose in this area and nanomaterials are a very promising model as DNA/RNA molecules vectors. Dystrophinopathies therefore represent a pivotal field of investigation, which has opened novel avenues in molecular biology, medical genetics and novel therapeutic options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
PLGA-based nanoparticles: An overview of biomedical applications
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 3,806
Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach
des Rieux, A., Fievez, V., Garinot, M., Schneider, Y.-J., & Préat, V. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.08.013 · Cited by 1,305
Dystrophin and mutations: one gene, several proteins, multiple phenotypes
Muntoni, F., Torelli, S., & Ferlini, A. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00585-4 · Cited by 1,124
Self-citationNanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60756-3 · Cited by 878
Eteplirsen for the treatment of Duchenne muscular dystrophy
Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., Lowes, L. P., Alfano, L., Gomez, A. M., Lewis, S., Kota, J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23982 · Cited by 817
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
Goemans, N. M., Tulinius, M., van den Akker, J. T., Burm, B. E., Ekhart, P. F., Heuvelmans, N., Holling, T., Janson, A. A., Platenburg, G. J., Sipkens, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011367 · Cited by 678
Dystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655
Kinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C., Guglieri, M., Ashton, E., Abbs, S., Nihoyannopoulos, P., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70211-x · Cited by 653
Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy
Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Fenichel, G. M., Miller, J. P., King, W., Signore, L., Pandya, S., Florence, J., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906153202405 · Cited by 520
Cell or Cell Membrane-Based Drug Delivery Systems
Tan, S., Wu, T., Zhang, D., & Zhang, Z. (2015) · Theranostics · doi:10.7150/thno.11852 · Cited by 466
Woodrow, K. A., Cu, Y., Booth, C. J., Saucier-Sawyer, J. K., Wood, M. J., & Mark Saltzman, W. (2009) · Nature Materials · doi:10.1038/nmat2444 · Cited by 438
Ataluren treatment of patients with nonsense mutation dystrophinopathy
Bushby, K., Finkel, R., Wong, B., Barohn, R., Campbell, C., Comi, G. P., Connolly, A. M., Day, J. W., Flanigan, K. M., Goemans, N., et al. (2014) · Muscle & Nerve · doi:10.1002/mus.24332 · Cited by 428
Biggar, W. D., Harris, V. A., Eliasoph, L., & Alman, B. (2006) · Neuromuscular Disorders · doi:10.1016/j.nmd.2006.01.010 · Cited by 371
Goyenvalle, A., Griffith, G., Babbs, A., Andaloussi, S. E., Ezzat, K., Avril, A., Dugovic, B., Chaussenot, R., Ferry, A., Voit, T., et al. (2015) · Nature Medicine · doi:10.1038/nm.3765 · Cited by 327
The Pathogenesis and Therapy of Muscular Dystrophies
Guiraud, S., Aartsma-Rus, A., Vieira, N. M., Davies, K. E., van Ommen, G.-J. B., & Kunkel, L. M. (2015) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090314-025003 · Cited by 302
Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy
King, W. M., Ruttencutter, R., Nagaraja, H. N., Matkovic, V., Landoll, J., Hoyle, C., Mendell, J. R., & Kissel, J. T. (2007) · Neurology · doi:10.1212/01.wnl.0000260974.41514.83 · Cited by 283
Toxicology of Nanomaterials Used in Nanomedicine
Zhao, J., & Castranova, V. (2011) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2011.615113 · Cited by 280
Moxley, R. T., Pandya, S., Ciafaloni, E., Fox, D. J., & Campbell, K. (2010) · Journal of Child Neurology · doi:10.1177/0883073810371004 · Cited by 280
Colussi, C., Mozzetta, C., Gurtner, A., Illi, B., Rosati, J., Straino, S., Ragone, G., Pescatori, M., Zaccagnini, G., Antonini, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805514105 · Cited by 275
Huizenga, N. A. T. M. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.1.144 · Cited by 265
Liposome-like nanostructures for drug delivery
Gao, W., Hu, C.-M. J., Fang, R. H., & Zhang, L. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb21238f · Cited by 244
Bonifati, M. D., Ruzza, G., Bonometto, P., Berardinelli, A., Gorni, K., Orcesi, S., Lanzi, G., & Angelini, C. (2000) · Muscle & Nerve · doi:10.1002/1097-4598(200009)23:9<1344::aid-mus4>3.0.co;2-f · Cited by 231
PREDNISONE IN DUCHENNE MUSCULAR DYSTROPHY
Drachman, D. B., Toyka, K. V., & Myer, E. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90071-3 · Cited by 212
Recent advances in delivery of drug–nucleic acid combinations for cancer treatment
Li, J., Wang, Y., Zhu, Y., & Oupický, D. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.010 · Cited by 207
Griggs, R. C., Moxley, R. T., Mendell, J. R., Fenichel, G. M., Brooke, M. H., Pestronk, A., Miller, J. P., Cwik, V. A., Pandya, S., Robison, J., et al. (1993) · Neurology · doi:10.1212/wnl.43.3_part_1.520 · Cited by 196
Heier, C. R., Damsker, J. M., Yu, Q., Dillingham, B. C., Huynh, T., Van der Meulen, J. H., Sali, A., Miller, B. K., Phadke, A., Scheffer, L., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302621 · Cited by 192
Lamprecht, A., Yamamoto, H., Takeuchi, H., & Kawashima, Y. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.088146 · Cited by 187
Tinsley, J. M., Fairclough, R. J., Storer, R., Wilkes, F. J., Potter, A. C., Squire, S. E., Powell, D. S., Cozzoli, A., Capogrosso, R. F., Lambert, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019189 · Cited by 185
Corticosteroid Treatment and Functional Improvement in Duchenne Muscular Dystrophy: Long-Term Effect
Balaban, B., Matthews, D. J., Clayton, G. H., & Carry, T. (2005) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/01.phm.0000184156.98671.d0 · Cited by 184
Deflazacort Use in Duchenne Muscular Dystrophy: An 8-Year Follow-Up
Houde, S., Filiatrault, M., Fournier, A., Dubé, J., D’Arcy, S., Bérubé, D., Brousseau, Y., Lapierre, G., & Vanasse, M. (2008) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2007.11.001 · Cited by 182
Consalvi, S., Mozzetta, C., Bettica, P., Germani, M., Fiorentini, F., Del Bene, F., Rocchetti, M., Leoni, F., Monzani, V., Mascagni, P., et al. (2013) · Molecular Medicine · doi:10.2119/molmed.2013.00011 · Cited by 167
A comprehensive genomic approach for neuromuscular diseases gives a high diagnostic yield
Ankala, A., da Silva, C., Gualandi, F., Ferlini, A., Bean, L. J. H., Collins, C., Tanner, A. K., & Hegde, M. R. (2015) · Annals of Neurology · doi:10.1002/ana.24303 · Cited by 167
Self-citationWasting mechanisms in muscular dystrophy
Shin, J. S., Tajrishi, M. M., Ogura, Y., & Kumar, A. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.001 · Cited by 161
Haas, M., Vlcek, V., Balabanov, P., Salmonson, T., Bakchine, S., Markey, G., Weise, M., Schlosser-Weber, G., Brohmann, H., Yerro, C. P., et al. (2015) · Neuromuscular Disorders · doi:10.1016/j.nmd.2014.11.011 · Cited by 160
Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy
Escolar, D. M., Hache, L. P., Clemens, P. R., Cnaan, A., McDonald, C. M., Viswanathan, V., Kornberg, A. J., Bertorini, T. E., Nevo, Y., Lotze, T., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318227b164 · Cited by 160
Polymeric micelles in mucosal drug delivery: challenges towards clinical translation
Sosnik, A., & Menaker Raskin, M. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.01.003 · Cited by 154
Pharmaceutical therapies to recode nonsense mutations in inherited diseases
Lee, H.-L. R., & Dougherty, J. P. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.007 · Cited by 145
Muthu, M. S., & Feng, S. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.729576 · Cited by 130
Gene therapy for muscular dystrophy: Lessons learned and path forward
Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Malik, V., Kaspar, B. K., Walker, C. M., & Clark, K. R. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.04.078 · Cited by 124
van Westering, T. L. E., Betts, C., & Wood, M. J. A. (2015) · Molecules · doi:10.3390/molecules20058823 · Cited by 120
Microarray-based mutation detection in thedystrophingene
Hegde, M., Chin, E., Mullé, J. G., Okou, D. T., Warren, S. T., & Zwick, M. E. (2008) · Human Mutation · doi:10.1002/humu.20831 · Cited by 119
Early corticosteroid treatment in 4 duchenne muscular dystrophy patients: 14‐year follow‐up
Merlini, L., Gennari, M., Malaspina, E., Cecconi, I., Armaroli, A., Gnudi, S., Talim, B., Ferlini, A., Cicognani, A., & Franzonı, E. (2012) · Muscle & Nerve · doi:10.1002/mus.23272 · Cited by 119
Self-citationCorticosteroids in Duchenne muscular dystrophy: Major variations in practice
Griggs, R. C., Herr, B. E., Reha, A., Elfring, G. L., Atkinson, L., Cwik, V. A., McColl, E., Tawil, R., Pandya, S., McDermott, M., et al. (2013) · Muscle & Nerve · doi:10.1002/mus.23831 · Cited by 118
Steroids in duchenne muscular dystrophy — Deflazacort trial
Mesa, L., Dubrovsky, A. L., Corderí, J., Marco, P., & Flores, D. (1991) · Neuromuscular Disorders · doi:10.1016/0960-8966(91)90099-e · Cited by 110
Wehling‐Henricks, M., Lee, J. J., & Tidball, J. G. (2004) · Neuromuscular Disorders · doi:10.1016/j.nmd.2004.04.008 · Cited by 110
A Chemical View of Oligonucleotides for Exon Skipping and Related Drug Applications
Järver, P., O’Donovan, L., & Gait, M. J. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0454 · Cited by 102
Naturally occurring utrophin correlates with disease severity in Duchenne muscular dystrophy
Kleopa, K. A., Drousiotou, A., Mavrikiou, E., Ormiston, A., & Kyriakides, T. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl083 · Cited by 102
PW1/Peg3 expression regulates key properties that determine mesoangioblast stem cell competence
Bonfanti, C., Rossi, G., Tedesco, F. S., Giannotta, M., Benedetti, S., Tonlorenzi, R., Antonini, S., Marazzi, G., Dejana, E., Sassoon, D., et al. (2015) · Nature Communications · doi:10.1038/ncomms7364 · Cited by 101
Cordani, N., Pisa, V., Pozzi, L., Sciorati, C., & Clementi, E. (2013) · Stem Cells · doi:10.1002/stem.1587 · Cited by 100
RNA-targeted splice-correction therapy for neuromuscular disease
Wood, M. J. A., Gait, M. J., & Yin, H. (2010) · Brain · doi:10.1093/brain/awq002 · Cited by 93
What Can We Learn From Clinical Trials of Exon Skipping for DMD?
Lu, Q., Çırak, S., & Partridge, T. A. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.6 · Cited by 92
Ferlini, A., Neri, M., & Gualandi, F. (2012) · Neuromuscular Disorders · doi:10.1016/j.nmd.2012.09.002 · Cited by 91
Self-citationLjubicic, V., Burt, M., & Jasmin, B. J. (2013) · The FASEB Journal · doi:10.1096/fj.13-238071 · Cited by 90
Second-generation compound for the modulation of utrophin in the therapy of DMD
Guiraud, S., Squire, S. E., Edwards, B., Chen, H., Burns, D. T., Shah, N., Babbs, A., Davies, S. G., Wynne, G. M., Russell, A. J., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv154 · Cited by 85
Bovolenta, M., Neri, M., Fini, S., Fabris, M., Trabanelli, C., Venturoli, A., Martoni, E., Bassi, E., Spitali, P., Brioschi, S., et al. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-572 · Cited by 84
Self-citationSali, A., Guerron, A. D., Gordish‐Dressman, H., Spurney, C. F., Iantorno, M., Hoffman, E. P., & Nagaraju, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034204 · Cited by 83
Anderson, J. E., Weber, M., & Vargas, C. (2000) · Cell Transplantation · doi:10.1177/096368970000900411 · Cited by 81
Current Treatment and Management of Dystrophinopathies
Goemans, N., & Buyse, G. (2014) · Current Treatment Options in Neurology · doi:10.1007/s11940-014-0287-4 · Cited by 75
Bosscher, K. D., Beck, I. M. E., & Haegeman, G. (2010) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2010.06.010 · Cited by 70
Wei, X., Dai, Y., Yu, P., Qu, N., Lan, Z., Hong, X., Sun, Y., Yang, G., Xie, S., Shi, Q., et al. (2013) · European Journal of Human Genetics · doi:10.1038/ejhg.2013.82 · Cited by 70
Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy
Ogura, Y., Tajrishi, M. M., Sato, S., Hindi, S. M., & Kumar, A. (2014) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2014.00011 · Cited by 60
Falzarano, M. S., Passarelli, C., & Ferlini, A. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0450 · Cited by 54
Self-citationTargeted Delivery of siRNA into Breast Cancer Cells via Phage Fusion Proteins
Bedi, D., Gillespie, J. W., Petrenko, V. A., Ebner, A., Leitner, M., Hinterdorfer, P., & Petrenko, V. A. (2012) · Molecular Pharmaceutics · doi:10.1021/mp3006006 · Cited by 50
Effects of exercise and steroid on skeletal muscle apoptosis in the mdx mouse
Lim, J. H., Kim, D., & Bang, M. S. (2004) · Muscle & Nerve · doi:10.1002/mus.20139 · Cited by 46
Wu, B., Cloer, C., Lu, P., Milazi, S., Shaban, M., Shah, S. N., Marston-Poe, L., Moulton, H. M., & Lu, Q. L. (2014) · Gene Therapy · doi:10.1038/gt.2014.53 · Cited by 44
D’Angelo, M. G., Gandossini, S., Boneschi, F. M., Sciorati, C., Bonato, S., Brighina, E., Comi, G. P., Turconi, A. C., Magri, F., Stefanoni, G., et al. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.01.006 · Cited by 44
Schairer, D. O., Martinez, L. R., Blecher, K., Chouake, J. S., Nacharaju, P., Gialanella, P., Friedman, J. M., Nosanchuk, J. D., & Friedman, A. (2012) · Virulence · doi:10.4161/viru.3.1.18816 · Cited by 44
Chérif, M. S., Shuaibu, M. N., Kurosaki, T., Helegbe, G. K., Kikuchi, M., Yanagi, T., Tsuboi, T., Sasaki, H., & Hirayama, K. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.09.031 · Cited by 41
The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy
Bonifati, D. M. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.078345 · Cited by 38
Therapy of Genetic Disorders: Novel Therapies for Duchenne Muscular Dystrophy
Seto, J. T., Bengtsson, N. E., & Chamberlain, J. S. (2014) · Current Pediatrics Reports · doi:10.1007/s40124-014-0044-x · Cited by 36
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Shen, J., Wu, X., Lee, Y., Wolfram, J., Yang, Z., Mao, Z., Mauro Ferrari, B., & Shen, H. (2015) · Journal of Visualized Experiments · doi:10.3791/52075 · Cited by 36
Review of Phase II and Phase III clinical trials for Duchenne muscular dystrophy
Scully, M. A., Pandya, S., & Moxley, R. T. (2012) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.746939 · Cited by 26
Noviello, M., Tedesco, F. S., Bondanza, A., Tonlorenzi, R., Carbone, M. R., Gerli, M., Marktel, S., Napolitano, S., Cicalese, M. P., Ciceri, F., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.62 · Cited by 24
Cited by
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
Frank, D. E., Schnell, F. J., Akana, C., El-Husayni, S. H., Desjardins, C. A., Morgan, J., Charleston, J. S., Sardone, V., Domingos, J., Dickson, G., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009233 · Cited by 332
Vignaud, J., Loiseau, C., Hérault, J., Mayer, C., Côme, M., Martin, I., & Ulmann, L. (2023) · Antioxidants · doi:10.3390/antiox12051050 · Cited by 72
Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy
Fortunato, F., Rossi, R., Falzarano, M. S., & Ferlini, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040820 · Cited by 64
Self-citationUnveiling the potential of antisense oligonucleotides: Mechanisms, therapies, and safety insights
Ersöz, E., & Demir‐Dora, D. (2024) · Drug Development Research · doi:10.1002/ddr.22187 · Cited by 34
Metadata
- Authors
- Falzarano, M., Scotton, C., Passarelli, C., & Ferlini, A.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2015-10-07
- Volume
- 20
- Issue
- 10
- Pages
- 18168-18184
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2171854062
- Cited by
- 292
- References
- 76
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.